A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV

Shu Hsing Cheng, Chia En Lien, Szu Min Hsieh, Chien Yu Cheng, Wang Da Liu, Ching Lung Lo, Wen Chien Ko, Yen Hsu Chen, Ching Tai Huang, Hsiao Ting Chang, Shinn Jang Hwang, Ning Chi Wang, Ming Che Liu, Yu Lin Lee, I. Chen Tai, Josue Antonio Garcia Estrada, Tzou Yien Lin, Wen Sen Lee

Research output: Contribution to journalArticlepeer-review

Abstract

Background: This study aimed to assess the safety and immunogenicity of MVC-COV1901, a recombinant COVID-19 protein vaccine, containing S-2P protein adjuvanted with CpG 1018 and aluminum hydroxide, for people living with HIV (PWH). Methods: A total of 57 PWH of ≥20 years of age who are on stable antiretroviral therapy were compared with 882 HIV-negative participants. Participants received two doses of MVC-COV1901 28 days apart. Results: No vaccine-related serious adverse events (SAEs) were recorded. Seroconversion rates (SCRs) of 100% and 99.8% were achieved in PWH and comparators, respectively, 28 days after the second dose. After adjusting for sex, age, BMI category, and comorbidity, the adjusted GMT ratio of comparator/PWH was 3.2 (95% CI 2.5–4). A higher CD4/CD8 ratio was associated with a higher GMT (R = 0.27, p = 0.039). MVC-COV1901 has shown robust safety but elicited weaker immune responses in PWH. Conclusions: Further investigations may be needed to determine whether PWH require distinct immunization strategies with improved immunogenicity. The main study is registered at ClinicalTrials.gov (NCT04695652).

Original languageEnglish
Article number18
JournalVaccines
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 2023

Keywords

  • CD4/CD8 ratio
  • COVID-19 vaccine
  • CpG 1018
  • HIV
  • immunogenicity
  • S-2P protein

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV'. Together they form a unique fingerprint.

Cite this